• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma.

作者信息

Pinato David J, Fessas Petros, Sapisochin Gonzalo, Marron Thomas U

机构信息

Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom.

Multi-Organ Transplant and HPB Surgical Oncology, Division of General Surgery, Toronto General Hospital, Department of Surgery, University of Toronto, Toronto, Canada.

出版信息

Hepatology. 2021 Jul;74(1):483-490. doi: 10.1002/hep.31697. Epub 2021 Jun 28.

DOI:10.1002/hep.31697
PMID:33369758
Abstract
摘要

相似文献

1
Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma.肝细胞癌免疫治疗新辅助应用的前景
Hepatology. 2021 Jul;74(1):483-490. doi: 10.1002/hep.31697. Epub 2021 Jun 28.
2
Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma.免疫检查点抑制剂治疗肝细胞癌的临床试验启示。
Front Immunol. 2021 Mar 30;12:652172. doi: 10.3389/fimmu.2021.652172. eCollection 2021.
3
Why Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better?辅助和新辅助治疗在肝癌中为何失败。新的免疫疗法有望表现得更好吗？
J Gastrointest Cancer. 2020 Dec;51(4):1193-1196. doi: 10.1007/s12029-020-00497-7.
4
Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy.晚期肝细胞癌的免疫联合治疗：塑造一线治疗方向
Future Oncol. 2021 Mar;17(7):755-757. doi: 10.2217/fon-2020-0986. Epub 2021 Jan 29.
5
Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).基于证据的肝细胞癌管理：系统评价和随机对照试验的荟萃分析 (2002-2020)。
Gastroenterology. 2021 Sep;161(3):879-898. doi: 10.1053/j.gastro.2021.06.008. Epub 2021 Jun 12.
6
Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China.中国肝细胞癌外科治疗的变化与挑战。
Biosci Trends. 2021 Jul 6;15(3):142-147. doi: 10.5582/bst.2021.01083. Epub 2021 Mar 14.
7
Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.肝细胞癌免疫治疗中靶向肿瘤相关抗原：过去的困境与未来策略
Hepatology. 2021 Feb;73(2):821-832. doi: 10.1002/hep.31502.
8
Adjuvant therapy in renal cell carcinoma: is resection still solely enough?肾细胞癌的辅助治疗：单纯手术切除是否仍然足够？
Future Oncol. 2021 Feb;17(6):633-636. doi: 10.2217/fon-2020-0982. Epub 2020 Dec 11.
9
Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.肝细胞癌的新辅助和辅助治疗策略。
World J Gastroenterol. 2019 Jul 28;25(28):3704-3721. doi: 10.3748/wjg.v25.i28.3704.
10
Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.术后辅助经导管动脉化疗栓塞治疗伴微血管侵犯的肝细胞癌患者的疗效。
World J Gastroenterol. 2017 Nov 7;23(41):7415-7424. doi: 10.3748/wjg.v23.i41.7415.

引用本文的文献

1
Current Advances in Classification, Prediction and Management of Microvascular Invasion in Hepatocellular Carcinoma.肝细胞癌微血管侵犯的分类、预测及管理的当前进展
J Cell Mol Med. 2025 Aug;29(15):e70746. doi: 10.1111/jcmm.70746.
2
α-Fetoprotein model versus Milan criteria in predicting outcomes after hepatic resection for hepatocellular carcinoma: multicentre study.甲胎蛋白模型与米兰标准在预测肝细胞癌肝切除术后结局中的比较：多中心研究
BJS Open. 2025 Mar 4;9(2). doi: 10.1093/bjsopen/zraf041.
3
Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis.
信迪利单抗联合贝伐珠单抗治疗中期肝细胞癌后行手术切除：一项伴有生物标志物分析的Ib期临床试验
BMJ Oncol. 2024 Dec 16;3(1):e000578. doi: 10.1136/bmjonc-2024-000578. eCollection 2024.
4
Tertiary lymphoid structure-related score as a predictor for survival prognosis and immunotherapy response in head and neck squamous cell carcinoma.三阴性乳腺癌相关评分作为预测头颈部鳞状细胞癌生存预后和免疫治疗反应的指标。
Front Immunol. 2024 Oct 18;15:1483497. doi: 10.3389/fimmu.2024.1483497. eCollection 2024.
5
Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance.探讨免疫微环境在肝细胞癌中的作用：对免疫治疗和耐药性的影响。
Elife. 2024 Aug 15;13:e95009. doi: 10.7554/eLife.95009.
6
Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review.免疫治疗时代肝细胞癌的病理评估：一篇叙述性综述
Hepatobiliary Surg Nutr. 2024 Jun 1;13(3):472-493. doi: 10.21037/hbsn-22-527. Epub 2023 Apr 4.
7
An updated review of immunotherapy in esophageal cancer: PD-L1 footprint.食管癌免疫治疗的最新综述：程序性死亡配体1印记
Cent Eur J Immunol. 2024;49(1):77-90. doi: 10.5114/ceji.2024.139269. Epub 2024 May 9.
8
Case report: Massive hepatocellular carcinoma with complete response to the non-surgical systematic treatment strategy.病例报告：巨大肝细胞癌对非手术系统性治疗策略完全缓解。
Front Oncol. 2024 May 10;14:1291131. doi: 10.3389/fonc.2024.1291131. eCollection 2024.
9
Hypomethylation-enhanced CRTC2 expression drives malignant phenotypes and primary resistance to immunotherapy in hepatocellular carcinoma.低甲基化增强的CRTC2表达驱动肝细胞癌的恶性表型和对免疫治疗的原发性耐药。
iScience. 2024 Apr 26;27(6):109821. doi: 10.1016/j.isci.2024.109821. eCollection 2024 Jun 21.
10
Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status.肝细胞癌免疫微环境与检查点抑制剂——现状
World J Hepatol. 2024 Mar 27;16(3):353-365. doi: 10.4254/wjh.v16.i3.353.